Filtered By:
Specialty: Research
Condition: Bleeding
Management: Health Insurance

This page shows you your search results in order of date.

Order by Relevance | Date

Total 7 results found since Jan 2013.

Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
CONCLUSIONS: These results suggest that rivaroxaban is an effective and safe treatment option among NVAF patients with obesity in a commercially-insured US population.PMID:33733969 | DOI:10.1080/03007995.2021.1901223
Source: Current Medical Research and Opinion - March 18, 2021 Category: Research Authors: Jeffrey S Berger Fran çois Laliberté Akshay Kharat Dominique Lejeune Kenneth Todd Moore Young Jung Patrick Lefebvre Veronica Ashton Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients. PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health.
CONCLUSION: This study demonstrated the value of supplementing longitudinal site-based clinical studies with administrative claims data. Our results suggest that claims data together with network partner electronic health record data constitute an effective vehicle to capture patient outcomes since >30% of patients have non-fatal and fatal events outside of enrolling sites. PMID: 31081367 [PubMed - as supplied by publisher]
Source: Clinical Trials - May 12, 2019 Category: Research Authors: Ma Q, Chung H, Shambhu S, Roe M, Cziraky M, Jones WS, Haynes K Tags: Clin Trials Source Type: research

Evaluating the Primary Prevention of Ischemic Stroke of Oral Antithrombotic Therapy in Head and Neck Cancer Patients with Radiation Therapy.
Abstract Although previous studies demonstrated the risk of ischemic stroke (IS) in patients with head and neck cancer (HNC), the impact of oral antithrombotic therapy (OAT) on this risk has not yet been assessed. We aimed to evaluate the effectiveness and safety of OAT in patients with HNC treated with RT. This retrospective cohort study was performed using the National Health Insurance Research Database of Taiwan. A total of 37,638 patients diagnosed with HNC included in the study were classified as users and nonusers of OAT. Primary outcome was IS or transient ischemic attack (TIA), and secondary outcomes were ...
Source: Biomed Res - December 20, 2016 Category: Research Authors: Hsu CW, Huang YB, Kuo CC, Chen CY Tags: Biomed Res Int Source Type: research